Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
268.46
-2.56 (-0.94%)
At close: Mar 28, 2025, 4:00 PM
266.00
-2.46 (-0.92%)
After-hours: Mar 28, 2025, 7:58 PM EDT

Alnylam Pharmaceuticals Stock Forecast

Stock Price Forecast

The 22 analysts with 12-month price forecasts for Alnylam Pharmaceuticals stock have an average target of 319.27, with a low estimate of 220 and a high estimate of 500. The average target predicts an increase of 18.93% from the current stock price of 268.46.

Analyst Consensus: Strong Buy
Target Low Average Median High
Price $220 $319.27 $320 $500
Change -18.05% +18.93% +19.20% +86.25%

Analyst Ratings

The average analyst rating for Alnylam Pharmaceuticals stock from 23 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating Oct '24Nov '24Dec '24Jan '25Feb '25Mar '25
Strong Buy 101010101010
Buy 777889
Hold 655543
Sell 011111
Strong Sell 000000
Total 232323242323

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
JP Morgan
JP Morgan
Buy
Upgrades
$280$328
Buy Upgrades $280$328 +22.18% Mar 24, 2025
Citigroup
Citigroup
Strong Buy
Maintains
$338$351
Strong Buy Maintains $338$351 +30.75% Mar 21, 2025
Canaccord Genuity
Canaccord Genuity
Strong Buy
Maintains
$385$390
Strong Buy Maintains $385$390 +45.27% Mar 21, 2025
RBC Capital
RBC Capital
Buy
Maintains
$310$330
Buy Maintains $310$330 +22.92% Mar 21, 2025
Scotiabank
Scotiabank
Buy
Maintains
$300$338
Buy Maintains $300$338 +25.90% Mar 21, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
2.95B
from 2.25B
Increased by 31.04%
Revenue Next Year
3.64B
from 2.95B
Increased by 23.56%
EPS This Year
-1.67
from -2.18
EPS Next Year
1.03
from -1.67
Fiscal Year FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026 FY 2027
Period Ending Dec 31, 2020 Dec 31, 2021 Dec 31, 2022 Dec 31, 2023 Dec 31, 2024 Dec 31, 2025 Dec 31, 2026 Dec 31, 2027
Revenue
492.85M844.29M1.04B1.83B2.25B2.95B3.64B4.66B
Revenue Growth
124.28%71.31%22.88%76.24%22.97%31.04%23.56%28.10%
EPS
-7.46-7.20-9.30-3.52-2.18-1.671.035.07
EPS Growth
-------391.44%
Forward PE
------260.3752.98
No. Analysts -----343221
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 20252026202720282029
High 3.6B 4.3B 5.9B
Avg 2.9B 3.6B 4.7B
Low 2.4B 3.1B 3.7B

Revenue Growth

Revenue Growth 20252026202720282029
High
62.2%
46.0%
63.4%
Avg
31.0%
23.6%
28.1%
Low
7.9%
5.6%
0.5%

EPS Forecast

EPS 20252026202720282029
High 1.13 6.47 10.82
Avg -1.67 1.03 5.07
Low -3.55 -2.24 2.01

EPS Growth

EPS Growth 20252026202720282029
High - -
948.9%
Avg - -
391.4%
Low - -
94.8%
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.